IJCM  Vol.5 No.21 , December 2014
Clinical Trial Phases
Author(s) Vicki L. Mahan
ABSTRACT
Developers of drugs, biologicals, and medical devices must ensure product safety, demonstrate medical benefit in people, and mass produce the product. Preclinical development starts before clinical trials and the main goals are to determine safety and effectiveness of the intervention. If preclinical studies show that the therapy is safe and effective, clinical trials are started. Clinical trial phases are steps in the research to determine if an intervention would be beneficial or detrimental to humans and include Phases 0, I, II, III, IV, and V clinical studies. Understanding the basis of clinical trial phases will help researchers plan and implement clinical study protocols and, by doing so, improve the number of therapies coming to market for patients.

Cite this paper
Mahan, V. (2014) Clinical Trial Phases. International Journal of Clinical Medicine, 5, 1374-1383. doi: 10.4236/ijcm.2014.521175.
References
[1]   Browne, L.H. and Graham, P.H. (2014) Good Intentions and ICU-GCP: Trial Conduct Training Needs to Go beyond the ICH-GCP Document and include the Intention-to-Treat Principle. Clinical Trials, 11, 629-634.
http://dx.doi.org/10.1177/1740774514542620

[2]   Ohmann, C., Kuchinke, W., Canham, S., Lauritsen, J., Salas, N., Schade-Brittinger, C., et al. (2011) Standard Requirements for GCP-Compliant Data Management in Multinational Clinical Trials. Trials, 12, 85.
http://dx.doi.org/10.1186/1745-6215-12-85

[3]   Rock, E.P., Molloy, V.J. and Humphrey, J.S. (2010) GCP Data Quality for Early Clinical Development. Clinical Cancer Research, 16, 1756-1763.
http://dx.doi.org/10.1158/1078-0432.CCR-09-3267

[4]   Switula, D. (2000) Principles of Good Clinical Practice (GCP) in Clinical Research. Science and Engineering Ethics, 6, 71-77.
http://dx.doi.org/10.1007/s11948-000-0025-z

[5]   Vijayananthan, A. and Nawawi, O. (2008) The Importance of Good Clinical Practice Guidelines and Its Role in Clinical Trials. Biomedical Imaging and Intervention Journal, 4, e5.
http://dx.doi.org/10.2349/biij.4.1.e5

[6]   Chalmers, T.C., Smith, H., Blackburn, B., Silverman, B., Schroeder, B., Reitman, D., et al. (1981) A Method for Assessing the Quality of a Randomized Control Trial. Controlled Clinical Trials, 2, 31-49.
http://dx.doi.org/10.1016/0197-2456(81)90056-8

[7]   Haahr, M.T. and Hróbjartsson, A. (2006) Who Is Blinded in Randomized Clinical Trials? A Study of 200 Trials and a Survey of Authors. Clinical Trials, 3, 360-365.

[8]   Jadad, A.R., Moore, R.A., Carroll, D., Jenkinson, C., Reynolds, J.M., Gavaghan, D.J., et al. (1996) Assessing the Quality of Reports of Randomizing Clinical Trials: Is Blinding Necessary? Controlled Clinical Trials, 17, 1-12.
http://dx.doi.org/10.1016/0197-2456(95)00134-4

[9]   Moher, D., Jadad, A.R., Nichol, G., Penman, M., Tugwell, P. and Walsh, S. (1995) Assessing the Quality of Randomized Controlled Trials: An Annotated Bibliography of Scales and Checklists. Controlled Clinical Trials, 16, 62-73.
http://dx.doi.org/10.1016/0197-2456(94)00031-W

[10]   Torgerson, D.J. and Roland, M. (1998) What Is Zelen’s Design. British Medical Journal, 316, 606-608.
http://dx.doi.org/10.1136/bmj.316.7131.606

[11]   E-Source Behavioral & Social Sciences Research. Clinical Trials.
www.esourceresearch.org

[12]   Stanley, K. (2007) Design of Randomized Controlled Trials. Circulation, 115, 1164-1169.
http://dx.doi.org/10.1161/CIRCULATIONAHA.105.594945

[13]   Avins, A.L. (1998) Can Unequal Be More Fail? Ethics, Subject Allocation, and Randomised Clinical Trials. Journal of Medical Ethics, 24, 401-408.
http://dx.doi.org/10.1136/jme.24.6.401

[14]   Lachin, J.M., Matts, J.P. and Wei, L.J. (1988) Randomization in Clinical Trials: Conclusions and Recommendations. Controlled Clinical Trials, 9, 365-374.
http://dx.doi.org/10.1016/0197-2456(88)90049-9

[15]   Schulz, K.F. and Grimes, D.A. (2002) Generation of Allocation Sequences in Randomised Trials: Chances, Not Choice. The Lancet, 359, 515-519.
http://dx.doi.org/10.1016/S0140-6736(02)07683-3

[16]   Sibbald, B. and Roland, M. (1998) Understanding Controlled Trials: Why Are Randomised Controlled Trials Important? BMJ, 316, 201-203.
http://dx.doi.org/10.1136/bmj.316.7126.201

[17]   Thall, P.F. and Wathen, J.K. (2007) Practical Bayesian Adaptive Randomization in Clinical Trials. European Journal of Cancer, 43, 859-866.
http://dx.doi.org/10.1016/j.ejca.2007.01.006

[18]   DeMets, D., Friedman, L. and Furberg, C. (2010) Fundamentals of Clinical Trials. 4th Edition, Springer, Berlin.

[19]   Rogers, M.A. (2009) What Are the Phases of Intervention Research? American Speech-Language-Hearing Association, Rockville.

[20]   Becich, M.J. (2007) Lessons Learned from the Shared Pathology Informatics Network (SPIN): A Scalable Network for Tanslational Research and Public Health. Journal of the American Medical Informatics Association, 14, 534-535.
http://dx.doi.org/10.1197/jamia.M2477

[21]   US Department of Health and Human Services Food and Drug Administration (2012) Innovation or Stagnation: Challenges and Opportunity on the Critical Path to New Medical Products.
http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html.

[22]   Lloyd, I. (2002-2003) New Technologies, Products in Development, and Attrition Rates: R&D Revolution Still around the Corner. PARAXEL’s Pharmaceutical R&D Statistical Sourcebook. PAREXEL International Corporation, Waltham.

[23]   Boston Consulting Group (2002-2003) A Revolution in R&D: How Genomics and Genetics Will Affect Drug Development Costs and Times. PARAXEL’s Pharmaceutical R&D Statistical Sourcebook. PAREXEL International Corporation, Waltham.

[24]   Kinders, R., Parchment, R.E., Ji, J., Kummar, S., Murgo, A.J., Gutierrez, M., et al. (2007) Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice. Molecular Interventions, 7, 325-334.
http://dx.doi.org/10.1124/mi.7.6.9

[25]   Kummar, S., Kinders, R., Rubinstein, L., Parchment, R.E., Murgo, A.J., Collins, J., et al. (2007) Compressing Drug Development Timelines in Oncology Using Phase “0” Trials. Nature Reviews Cancer, 7, 131-139.
http://dx.doi.org/10.1038/nrc2066

[26]   Marchetti, S. and Schellens, J.H.M. (2007) The Impact of FDA and EMEA Guidelines on Drug Development in Relation to Phase 0 Trials. British Journal of Cancer, 97, 577-581.
http://dx.doi.org/10.1038/sj.bjc.6603925

[27]   Schellens, J.H.M. (2009) Phase 0 (Zero) Clinical Trials: More than Zero Benefits? European Journal of Cancer, 45, 728-729.
http://dx.doi.org/10.1016/j.ejca.2009.01.022

[28]   Le Tourneau, C., Lee, J.J. and Siu, L.L. (2009) Dose Escalation Methods in Phase I Cancer Clinical Trials. Journal of the National Cancer Institute, 101, 708-720.
http://dx.doi.org/10.1093/jnci/djp079

[29]   Storer, B.E. (1989) Design and Analysis of Phase I Clinical Trials. Biometrics, 45, 795-798.
http://dx.doi.org/10.2307/2531693

[30]   Rogatko, A., Schoeneck, D., Jonas, W., Tighiouart, M., Khuri, F.R. and Porter, A. (2007) Translation of Innovative Designs into Phase I Trials. Journal of Clinical Oncology, 25, 4982-4986.
http://dx.doi.org/10.1200/JCO.2007.12.1012

[31]   Storer, B.E. (2001) An Evaluation of Phase I Clinical Trial Designs in the Continuous Dose-Response Setting. Statistics in Medicine, 20, 2399-2408.
http://dx.doi.org/10.1002/sim.903

[32]   Graham, M.A. and Workman, P. (1992) The Impact of Pharmacokinetically Guided Dose Escalation Strategies in Phase I Clinical Trials: Critical Evaluation and Recommendations for Future Studies. Annals of Oncology, 3, 339-347.

[33]   Leung, D.H. and Wang, Y. (2001) Isotonic Designs for Phase I Trials. Controlled Clinical Trials, 22, 126-138.
http://dx.doi.org/10.1016/S0197-2456(00)00132-X

[34]   Skolnick, J.M., Barrett, J.S., Jayaraman, B., Patel, D. and Adamson, P.C. (2008) Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design. Journal of Clinical Oncology, 26, 190-195.
http://dx.doi.org/10.1200/JCO.2007.12.7712

[35]   Durham, S.D., Flournoy, N. and Rosenberger, W.F. (1997) A Random Walk Rule for Phase I Clinical Trials. Biometrics, 53, 745-760.
http://dx.doi.org/10.2307/2533975

[36]   Ivanova, A., Montazer-Haghighi, A., Mohanty, S.G. and Durham, S.D. (2003) Improved Up-and-Down Designs for Phase I Trials. Statistics in Medicine, 22, 69-82.
http://dx.doi.org/10.1002/sim.1336

[37]   Stylianou, M. and Follmann, D.A. (2004) The Accelerated Biased Coin Up-and-Down Design in Phase I Trials. Journal of Biopharmaceutical Statistics, 14, 249-260.
http://dx.doi.org/10.1081/BIP-120028518

[38]   Ji, Y., Li, Y. and Nebiyou Bekele, B. (2007) Dose-Finding in Phase I Clinical Trials Based on Toxicity Probability Intervals. Clinical Trials, 4, 235-244.
http://dx.doi.org/10.1177/1740774507079442

[39]   O’Quigley, J., Pepe, M. and Fisher, L. (1990) Continual Reassessment Method: A Practical Design for Phase I Clinical Trials in Cancer. Biometrics, 46, 33-48.
http://dx.doi.org/10.2307/2531628

[40]   Faries, D. (1994) Practical Modifications of the Continual Reassessment Method for Phase I Cancer Clinical Trials. Journal of Biopharmaceutical Statistics, 4, 147-164.
http://dx.doi.org/10.1080/10543409408835079

[41]   Goodman, S.N., Zahurk, M.L. and Piantadosi, S. (1995) Some Practical Improvements in the Continual Reassessment Method for Phase I Studies. Statistics in Medicine, 14, 1149-1161.
http://dx.doi.org/10.1002/sim.4780141102

[42]   Moller, S. (1995) An Extension of the Continual Reassessment Methods Using a Preliminary Up-and-Down Design in a Dose Finding Study in Cancer Patients in Order to Investigate a Greater Range of Doses. Statistics in Medicine, 14, 911-922.
http://dx.doi.org/10.1002/sim.4780140909

[43]   Piantadosi, S., Fisher, J.D. and Grossman, S. (1998) Practical Implementation of a Modified Continual Reassessment Method for Dose-Finding Trials. Cancer Chemotherapy and Pharmacology, 41, 429-436.
http://dx.doi.org/10.1007/s002800050763

[44]   Rogatko, A., Babb, J.S., Tighiouart, M., Khuri, F.R. and Hudes, G. (2005) New Paradigm in Dose-Finding Trials: Patient-Specific Dosing and Beyond Phase I. Clinical Cancer Research, 11, 5342-5346.
http://dx.doi.org/10.1158/1078-0432.CCR-05-0458

[45]   Riviere, M.K., Le Tourneau, C., Paoletti, X., Dubois, F. and Zohar, S. (2014) Designs of Drug-Combination Phase I Trials in Oncology: A Systematic Review of the Literature. Annals of Oncology.
http://dx.doi.org/10.1093/annonc/mdu516

[46]   Gehan, E.A. (1961) The Determination of the Number of Patients Required in a Preliminary and a Follow-Up Trial of a New Chemotherapeutic Agent. Journal of Chronic Diseases, 13, 346-353.
http://dx.doi.org/10.1016/0021-9681(61)90060-1

[47]   Gehan, E.A. (1986) Update on Planning of Phase II Clinical Trials. Drugs under Experimental and Clinical Research, 12, 43-50.

[48]   Coffey, C.S. and Kairalla, J.A. (2008) Adaptive Clinical Trials: Progress and Challenges. Drugs in R&D, 9, 229-242.
http://dx.doi.org/10.2165/00126839-200809040-00003

[49]   US Food and Drug Administration (2010) Draft Guidance for Industry-Adaptive Design Clinical Trials for Drugs and Biologics. US Food Drug Admin, Rockville.

[50]   Chow, S.C., Chang, M. and Pong, A. (2005) Statistical Consideration of Adaptive Methods in Clinical Development. Journal of Biopharmaceutical Statistics, 15, 575-591.
http://dx.doi.org/10.1081/BIP-200062277

[51]   Pazdur, R. (2008) Endpoints for Assessing Drug Activity in Clinical Trials. The Oncologist, 13, 19-21.
http://dx.doi.org/10.1634/theoncologist.13-S2-19

[52]   Ocana, A., Amir, E., Vera-Badillo, F., Seruga, B. and Tannock, I.F. (2013) Phase III Trials of Targeted Anticancer Therapies: Redesigning the Concept. Cancer Research, 19, 4931-4940.

[53]   Bauer, P. and Kohne, K. (1994) Evaluation of Experiments with Adaptive Interim Analyses. Biometrics, 50, 1029-1041.
http://dx.doi.org/10.2307/2533441

[54]   Proschan, M.A. and Hunsberger, S.A. (1995) Designed Extension of Studies Based on Conditional Power. Biometrics, 51, 1315-1324.
http://dx.doi.org/10.2307/2533262

[55]   Elsäßer, A., Regnstrom, J., Vetter, T., Koenig, F., Hemmings, R.J., Greco, M., et al. (2014) Adaptive Clinical Trial Designs for European Marketing Authorization: A Survey of Scientific Advice Letters from the European Medicines Agency. Trials, 15, 383.
http://dx.doi.org/10.1186/1745-6215-15-383

[56]   Mauer, M., Collette, L. and Bogaerts, J., European Organisation for Research and Treatment of Cancer (EORTC) Statistics Department (2012) Adaptive Designs at European Organisation for Research and Treatment of Cancer (EORTC) with a Focus on Adaptive Sample Size Re-Estimation Based on Interim-Effect Size. European Journal of Cancer, 48, 1386-1391.
http://dx.doi.org/10.1016/j.ejca.2011.12.024

[57]   Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs (2012) Ethical and Scientific Issues in Studying the Safety of Approved Drugs. Institute of Medicine of the National Academics, Washington DC.

[58]   Mello, M.M., Goodman, S.N. and Faden, R.R. (2012) Ethical Considerations in Studying Drug Safety—The Institute of Medicine Report. The New England Journal of Medicine, 367, 959-964.
http://dx.doi.org/10.1056/NEJMhle1207160

[59]   Bernabe, R.D.L.C., van Thiel, G.J.M.W., Raaijmakers, J.A.M. and van Delden, J.J.M. (2014) The Fiduciary Obligation of the Physician-Researcher in Phase IV Trials. BMC Medical Ethics, 15, 11.
http://dx.doi.org/10.1186/1472-6939-15-11

[60]   Fontanarosa, P.B., Rennie, D. and DeAngelis, C.D. (2004) Postmarketing Surveillance—Lack of Vigilance, Lack of Trust. Journal of the American Medical Association, 292, 2647-2650.
http://dx.doi.org/10.1001/jama.292.21.2647

[61]   van Thiel, G.J.M.W. and van Delden, J.J.M. (2008) Phase IV Research: Innovation in Need of Ethics. Journal of Medical Ethics, 34, 415-416.
http://dx.doi.org/10.1136/jme.2007.023911

[62]   Administration USFDA (2011) AERS Patient Outcomes by Year 2010.
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugE
ffects/ucm070461.htm


[63]   Strom, B.L. (2004) Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: A Counterpoint. Journal of the American Medical Association, 292, 2643-2646.
http://dx.doi.org/10.1001/jama.292.21.2643

[64]   Hennekens, C.H. and Demets, D. (2009) The Need for Large-Scale Randomized Evidence without Undue Emphasis on Small Trials, Meta-Analyses, or Subgroup Analyses. Journal of the American Medical Association, 302, 2361-2362.
http://dx.doi.org/10.1001/jama.2009.1756

[65]   Berlin, J.A. and Colditz, G.A. (1999) The Role of Meta-Analysis in the Regulatory Process for Foods, Drugs, and Devices. Journal of the American Medical Association, 281, 830-834.
http://dx.doi.org/10.1001/jama.281.9.830

[66]   Maro, J.C., Platt, R., Holmes, J.H., Strom, B.L., Hennessy, S., Lazarus, R., et al. (2009) Design of a National Distributed Health Data Network. Annals of Internal Medicine, 151, 341-344.
http://dx.doi.org/10.7326/0003-4819-151-5-200909010-00139

 
 
Top